SCHEDULE 13G/A: Redmile Group Discloses 7.0% Passive Stake in Zymeworks Inc.
Beneficial Ownership Disclosure
Redmile Group, LLC and its affiliates have disclosed a passive 7.0% beneficial ownership stake in Zymeworks Inc., holding 4,840,463 common shares as of December 31, 2024.
Summary
- Redmile Group, LLC, along with its principal Jeremy C. Green, and Redmile Biopharma Investments III, L.P., have filed an amended Schedule 13G for Zymeworks Inc.
- As of December 31, 2024, Redmile Group, LLC and Jeremy C. Green beneficially own 4,840,463 shares of Zymeworks Inc. common stock, representing 7.0% of the outstanding shares.
- Redmile Biopharma Investments III, L.P., a private investment vehicle managed by Redmile Group, LLC, directly owns 3,470,727 shares, equating to 5.0% of the common stock.
- The beneficial ownership is primarily held by various private investment vehicles managed by Redmile Group, LLC, with Redmile Group, LLC and Jeremy C. Green exercising shared voting and dispositive power over these shares.
- The percentage ownership is calculated based on 68,877,526 shares of Zymeworks Inc. common stock outstanding as of October 30, 2024, as reported in the company's Form 10-Q.
- The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Zymeworks Inc.
Sentiment
Score: 6
Explanation: The disclosure of a significant passive institutional stake by a specialized investor like Redmile Group is generally viewed as a positive signal of confidence in the company, although the filing itself is purely informational and does not contain operational news.
Positives
- A significant institutional investor like Redmile Group holding a 7.0% stake may signal confidence in Zymeworks Inc.'s long-term prospects.
- The passive nature of the investment, as stated in the filing, suggests that Redmile Group is not seeking to influence control, which can provide stability.
Future Outlook
NA
Industry Context
This filing indicates continued institutional interest in the biopharmaceutical sector, with Redmile Group, a specialized healthcare investor, maintaining a significant stake in Zymeworks Inc., a company operating in this industry. Such disclosures are common for publicly traded biopharma companies as institutional investors adjust their positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and trading activity.
- Potential Investors: Offers insight into the confidence of large institutional funds in Zymeworks Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-10-30 | Date as of which 68,877,526 shares of Common Stock were outstanding, as reported by Zymeworks Inc. in its Form 10-Q. |
| 2024-10-31 | Date Zymeworks Inc. filed its Form 10-Q for the quarterly period ended September 30, 2024. |
| 2024-12-31 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G statement was signed and filed by Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. |
Keywords
Zymeworks Inc., Redmile Group, LLC, Jeremy C. Green, Redmile Biopharma Investments III, L.P., Schedule 13G, beneficial ownership, institutional investor, common stock, biopharma, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.